Literature DB >> 30094264

Is there a beneficial effect of adding azathioprine to adalimumab in Crohn's disease patients?

Mark Löwenberg1.   

Abstract

Entities:  

Year:  2018        PMID： 30094264      PMCID： PMC6064807          DOI： 10.21037/atm.2018.06.36

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

Review 1.  Adalimumab monotherapy versus combination therapy with immunomodulators in patients with Crohn's disease: a systematic review and meta-analysis.

Authors:  Uri Kopylov; Talal Al-Taweel; Mohammad Yaghoobi; Benedicte Nauche; Alain Bitton; Peter L Lakatos; Shomron Ben-Horin; Waqqas Afif; Ernest G Seidman
Journal:  J Crohns Colitis       Date:  2014-07-25       Impact factor: 9.071

2.  Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.

Authors:  Henit Yanai; Lev Lichtenstein; Amit Assa; Yoav Mazor; Batia Weiss; Arie Levine; Yulia Ron; Uri Kopylov; Yoram Bujanover; Yoram Rosenbach; Bella Ungar; Rami Eliakim; Yehuda Chowers; Raanan Shamir; Gerald Fraser; Iris Dotan; Shomron Ben-Horin
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-25       Impact factor: 11.382

3.  Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

Authors:  Jean-Frédéric Colombel; William J Sandborn; Paul Rutgeerts; Robert Enns; Stephen B Hanauer; Remo Panaccione; Stefan Schreiber; Dan Byczkowski; Ju Li; Jeffrey D Kent; Paul F Pollack
Journal:  Gastroenterology       Date:  2006-11-29       Impact factor: 22.682

4.  Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Authors:  Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.

Authors:  Bella Ungar; Yehuda Chowers; Miri Yavzori; Orit Picard; Ella Fudim; Ofir Har-Noy; Uri Kopylov; Rami Eliakim; Shomron Ben-Horin
Journal:  Gut       Date:  2013-09-16       Impact factor: 23.059

Review 7.  The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis.

Authors:  Sandra Garcês; Jocelyne Demengeot; Elizabeth Benito-Garcia
Journal:  Ann Rheum Dis       Date:  2012-12-06       Impact factor: 19.103

8.  Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease.

Authors:  Y Mazor; R Almog; U Kopylov; D Ben Hur; A Blatt; A Dahan; M Waterman; S Ben-Horin; Y Chowers
Journal:  Aliment Pharmacol Ther       Date:  2014-07-15       Impact factor: 8.171

9.  Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors:  Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal:  Gastroenterology       Date:  2006-02       Impact factor: 22.682

10.  Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases.

Authors:  Bella Ungar; Idan Levy; Yarden Yavne; Miri Yavzori; Orit Picard; Ella Fudim; Ronen Loebstein; Yehuda Chowers; Rami Eliakim; Uri Kopylov; Shomron Ben-Horin
Journal:  Clin Gastroenterol Hepatol       Date:  2015-10-29       Impact factor: 11.382
View more
  1 in total

Review 1.  The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease.

Authors:  Fotios S Fousekis; Konstantinos Papamichael; Georgios Kourtis; Eleni N Albani; Afroditi Orfanidou; Maria Saridi; Konstantinos H Katsanos; Dimitrios K Christodoulou
Journal:  Ann Gastroenterol       Date:  2021-12-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.